Ascendis Pharma is committed to developing a proprietary pipeline of unique products that address unmet patient needs in rare endocrine diseases. Our ongoing clinical trials for TransCon Growth Hormone and TransCon PTH are a reflection of that commitment.
TransCon Growth Hormone
More about the heiGHt Trial
More about the fliGHt Trial
TransCon PTH (parathyroid hormone)
A phase 1 clinical trial is ongoing in healthy adults to evaluate the safety, tolerability and pharmacodynamics/pharmacokinetics of TransCon PTH.
*Children <3 may be treatment-naïve.
†Children <3 years of age only.
TransCon Growth Hormone and TransCon PTH are investigational products. GHD = growth hormone deficiency; hGH = human growth hormone; PTH = parathyroid hormone. The heiGHt Trial, fliGHt Trial and enliGHten Trial are sponsored by Ascendis Pharma Endocrinology Division A/S; a company in the Ascendis Pharma Group.